MDA is delighted to announce the 2023 MDA Clinical & Scientific Conference being held March 19-22, 2023, in Dallas, TX at the Hilton Anatole. On the heels of our extremely successful return to in-person events, we look forward to offering the NMD community our first-in-class conference once again both in person as well as virtually in 2023.
It goes without saying that the world around us has changed over the past two years in ways we never could have imagined. Fortunately, the search for neuromuscular disease (NMD) treatments was able to move forward throughout the pandemic as research laboratories and clinical trials quickly adapted to our new realities.
The Muscular Dystrophy Association (MDA)’s mission to empower the people we serve to live longer more independent lives continued and is happening right now through the ever-expanding pipeline of promise – 15 FDA approved drugs for neuromuscular disease in the last 12 years. Those treatments were created from MDA’s vision to open a new field of medicine and push the boundaries of the medical frontier we call genetic medicine.
In the 21st century, MDA leads the way in developing treatments and cures on that new medical frontier. For virtually all human history, people with a genetic disease had no hope of a treatment. People with progressive genetic diseases – the ones that get worse over time like muscular dystrophy and most neuromuscular diseases – had no hope of even slowing their disease’s relentless progress and gaining a longer life. Today, however, for the first time in history and for the first time in medicine, MDA-supported scientists and clinicians are helping develop the first FDA approved treatments for genetic diseases that are stopping some and slowing many others.
Hope for a longer, more independent life is now becoming a reality for thousands of patients with muscular dystrophy and related diseases. And the pipeline of promise – more life empowering treatments and cures – is growing and creating ever more hope for the millions of patients and their families who are at the heart of MDA’s mission and vision.
The 2023 Conference will explore all aspects of pre-clinical, translational, and clinical research and care across NMD to support the development of better care and treatments for our community. Once again, MDA is excited to work with our planning committee, session chairs and speakers to deliver unparalleled content.
Please join us for what is sure to be the not-to-miss conference for the NMD community. We look forward to gathering together again as we transform the lives of people affected by neuromuscular disease.
Donald S. Wood, Ph.D.
President and CEO
Muscular Dystrophy Association